Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRDFERON: Interferon alpha-2a vs Prednisone in Birdshot Chorioretinopathy
NCT00508040Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2007
- Primary completion
- Oct 2011
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon alfa-2a in Birdshot Chorioretinopathy (BCR) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Central foveal thickness at 4 months. Started Sep 2007; status: completed.
02
Drugs
interferon alfa-2a
03
Conditions
Birdshot Chorioretinopathy (BCR)
Beyond the preview
Go deeper on NCT00508040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508040.